Medovex Corporation Launches DenerveX In Switzerland
Published: Oct 05, 2017
ATLANTA, GA--(Marketwired - October 03, 2017) - Medovex Corp. (NASDAQ: MDVX) ("Medovex" or the "Company"), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to back pain, today announced that it has launched its DenerveX System Device in Switzerland with distributor Spine Surgical.
Switzerland is one of the most important locations for the global medical technology industry. There is no other country in which medical technology is of such great importance with regards to the overall GDP and the working population. By combining first-class research facilities and highly-developed healthcare systems -- an area in which demand for medical products and innovation is highly stimulated -- Switzerland presents itself as an extremely attractive location for research, development and production for the medical technology sector.
Switzerland is also considered to be an important strategic and clinical market for medical technology products thanks to its highly-developed and financially sound health care system. It is also one of the highest spenders on their healthcare system per capita, compared to other countries, making it an attractive sales market for medical device manufacturers.
Manfred Sablowski, Medovex Sr. Vice President of Sales and Marketing, stated, "We are excited to continue to roll out the DenerveX System to large and opportunistic markets such as Switzerland."
Sablowski concluded, "We developed the DenerveX System to enhance a patient's quality of life. The agony of pain associated with the Facet Joint can be life-altering, robbing people of even the simplest joys of daily life like bending over to hug a grandchild, taking a walk or gardening. Powerful painkillers often prescribed for severe back pain are fanning the flames of the nation's opioid epidemic. The DenerveX System involves a simple, minimally invasive, "keyhole" procedure that is designed to bring faster, longer-lasting relief."
Videos of leading spine surgeon Dr. Vik Kapoor talking about FJS and the DenerveX Device may be viewed at the following links:
Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in the United States and other countries in the EU and Rest of World affecting millions each year. Current treatment options are generally temporary and there is no proven long-lasting option for FJS.
The DenerveX System is a highly differentiated technology. It denervates and removes capsular tissue from the Facet Joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and RF ablation treatment on the Facet Joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint.
The DenerveX System consists of the DenerveX Kit which contains the DenerveX Device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet FDA cleared.
Please also follow us on Facebook at https://www.facebook.com/medovex/.
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.